[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341957-105":59,"doc-detail-341957-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","analytical-and-clinical-validation-of-a-ngs-panel-in-detecting-targetable-variants-from-ctdna-of-metastatic-nsclc-patients","Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients","","Circulating tumor DNA (ctDNA) functions as a noninvasive biomarker for metastatic non-small-cell lung cancer (NSCLC), enabling detection of actionable alterations when tumor tissue is limited. A next-generation sequencing panel targeting 101 cancer-related genes (101-test) was developed and evaluated for analytical performance by limit of detection, accuracy, and precision, and for clinical concordance with tissue in 904 Chinese patients. Results show high sensitivity and specificity for somatic variant detection and substantial agreement between ctDNA and tissue, with a subset identified only by ctDNA.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/analytical-and-clinical-validation-of-a-ngs-panel-in-detecting-targetable-variants-from-ctdna-of-metastatic-nsclc-patients/341957/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/analytical-and-clinical-validation-of-a-ngs-panel-in-detecting-targetable-variants-from-ctdna-of-metastatic-nsclc-patients/341957.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of the 101-test in this study?","Question",{"text":112,"@type":113},"The 101-test is designed to detect somatic targetable variants from ctDNA in patients with metastatic NSCLC using a next-generation sequencing panel targeting 101 cancer-related genes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was analytical performance assessed for the NGS panel?",{"text":117,"@type":113},"Analytical performance was evaluated using limit of detection (LOD), accuracy, and precision, and compared against reference methods using digital droplet PCR and breakpoint PCR.",{"name":119,"@type":110,"acceptedAnswer":120},"How well did ctDNA testing agree with tissue testing for targetable variants?",{"text":121,"@type":113},"In a real-world cohort, concordance between ctDNA and tissue samples for identifying targetable variants was 72.2%, and some patients had targetable variants detected exclusively through ctDNA testing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341957,1790108222,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","DOI: 10. 1002/cam4 .70078  \nRESEAR CH ARTICLE  \nAnalytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients  \nFeifei Fan1 | Guozhong Jiang2  | Juan Lv3 | Hongmin Wang1 | Wenjie Li3 | Chenglin Liu3 | Yu Zhao3 | Zhou Zhang3 | Haiwei Du3 | Zhihong Zhang3 | Xiangnan Li4 | Wen-cai Li2   \n1Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China  \n2Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China 3Burning Rock Biotech, Guangzhou, China  \n4Department of Thoracic Surgery and Lung Transplantation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China  \nCorrespondence  \nZhihong Zhang, Burning Rock Biotech, Guangzhou, China.  \nEmail: [zhihong.zhang@brbiotech.com](zhihong.zhang@brbiotech.com)  \nXiangnan Li, Department of Thoracic Surgery and Lung Transplantation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.  \nEmail: [lxn-2000@163.com](lxn-2000@163.com)  \nWencai Li, Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.  \nEmail: [liwencai@zzu.edu.cn](liwencai@zzu.edu.cn)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Number: 82172941  \nAbstract  \nBackground: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for noninvasive cancer diagnostics, particularly in the context of metastatic non-small-cell lung cancer (NSCLC). Detecting targetable variants through ctDNA analysis offers the potential to guide treatment decisions, especially in cases where tissue samples are insufficient or unavailable.  \nMethod: In this study, we developed and validated a next-generation sequencing panel targeting 101 cancer-related genes (101-test) to detect somatic variants inctDNA from a large cohort of Chinese patients with metastatic NSCLC. The performance of the 101-test was assessed by evaluating its limit of detection (LOD), accuracy, and precision in identifying molecular variants. Additionally, the concordance between ctDNA and tissue samples for detecting targetable variants was analyzed in 904 patients.  \nResults: The 101-test demonstrated a LOD of 0.38% for single-nucleotide variants (SNVs), 0. 33% for insertions and deletions (InDels), and 0. 33% for fusions. Sensitivity was 98.3% for SNVs, 100% for InDels, and 100% for fusions when compared to digital droplet PCR (ddPCR)/breakpoint PCR reference methods. The by-variant sensitivity for somatic variants was 97.5%, with a specificity of 99.9% between tumor-only and tumor-normal analyses. In a real-world cohort, the concordance between ctDNA and tissue samples for identifying targetable variants was 72.2%(457/633) . Notably, the EGFR S768I variant, recently recommended by clinical guidelines, achieved an 80% concordance rate. Furthermore, 4.3% of patients (27/633) with targetable variants were identified exclusively through ctDNA testing.  \nFeifei Fan, Guozhong Jiang, and Juan Lv contribute to this work equally.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nConclusion: The ctDNA-based 101-test is a highly sensitive and specific tool for detecting targetable variants in metastatic NSCLC, particularly in cases with insufficient tissue samples. The findings support the use of ctDNA testing as a reliable and complementary method to traditional tissue-based molecular analysis, enhancing the precision of treatment strategies for NSCLC patients.  \nKEYWORDS  \ncirculating tumor DNA, concordance, next-generation sequencing, targetable variants, tissue sample  \n1 | INTRODUCTION  \nLung cancer is the leading cause of cancer-related death worldwide and in China.1,2 Non-small cell lung canc","cbCaihurxfx1aeLi","https://ap.wps.com/l/cbCaihurxfx1aeLi","pdf",2096702,12,"English","# Abstract\n## Background\n## Method\n## Results\n## Conclusion\n# Introduction\n# Materials and Methods\n## Healthy donors","[{\"question\":\"What is the purpose of the 101-test in this study?\",\"answer\":\"The 101-test is designed to detect somatic targetable variants from ctDNA in patients with metastatic NSCLC using a next-generation sequencing panel targeting 101 cancer-related genes.\"},{\"question\":\"How was analytical performance assessed for the NGS panel?\",\"answer\":\"Analytical performance was evaluated using limit of detection (LOD), accuracy, and precision, and compared against reference methods using digital droplet PCR and breakpoint PCR.\"},{\"question\":\"How well did ctDNA testing agree with tissue testing for targetable variants?\",\"answer\":\"In a real-world cohort, concordance between ctDNA and tissue samples for identifying targetable variants was 72.2%, and some patients had targetable variants detected exclusively through ctDNA testing.\"}]","Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients | PDF",1790044509,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d543ec8f9a3bb93eb41e5efe306db11c.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9f7f0a217603417e47bd5f91f055361.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dd0c5b75d5905814f41521373ba34b5.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c105482e22b178bbc70e7d0380164181.webp",980,1287]